Molecule
Methylphenidate is a central nervous system stimulant indicated for the treatment of attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults, among other approved uses. MedsAcross supplies Methylphenidate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Ritalin is indicated for the treatment of: • Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults • Narcolepsy Ritalin is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy.
Source: US FDA prescribing information
Methylphenidate hydrochloride is a CNS stimulant. The mode of therapeutic action in ADHD and narcolepsy is not known.
Source: US FDA prescribing information
• Pediatric Patients 6 Years and Older: Start with 5 mg twice daily (before breakfast and lunch), titrating the dose weekly in 5- to 10-mg increments. Dosages above 60 mg/day are not recommended. • Adults: Average daily dosage is 20 mg to 30 mg, administered 2 or 3 times daily, preferably 30 to 45 minutes before meals. Maximum total daily dosage is 60 mg.
Source: US FDA prescribing information
• Hypersensitivity to methylphenidate or other components of Ritalin. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported in patients treated with methylphenidate. • Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises. • Known hypersensitivity to methylphenidate or other product components of Ritalin. • Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days.
Source: US FDA prescribing information
Boxed warning (abuse, misuse, and addiction): Ritalin has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Ritalin, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. • Risks to Patients with Serious Cardiac Disease: Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. • Increased Blood Pressure and Heart Rate: Monitor blood pressure and pulse. • Psychiatric Adverse Reactions: Prior to initiating Ritalin, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing Ritalin.
Source: US FDA prescribing information
The following are discussed in more detail in other sections of the labeling: • Abuse, Misuse, and Addiction • Known hypersensitivity to methylphenidate or other ingredients of Ritalin • Hypertensive crisis with Concomitant Use of Monoamine Oxidase Inhibitors • Risks to Patients with Serious Cardiac Disease • Increased Blood Pressure and Heart Rate • Psychiatric Adverse Reactions • Priapism • Peripheral Vasculopathy, Including Raynaud’s Phenomenon • Long-Term Suppression of Growth in Pediatric Patients • Acute Angle Closure Glaucoma • Increased Intraocular Pressure and Glaucoma • Motor and Verbal Tics, and Worsening of Tourette’s Syndrome The following adverse reactions associated with the use of Ritalin and other methylphenidate products were identified in clinical trials, spontaneous reports, and literature.
Source: US FDA prescribing information
• Antihypertensive Drugs: Monitor blood pressure. Adjust dosage of antihypertensive drug as needed. Clinically Important Drug Interactions with Ritalin Table 1 presents clinically important drug interactions with Ritalin. Table 1: Clinically Important Drug Interactions with Ritalin Monoamine Oxidase Inhibitors (MAOI) Clinical Impact Concomitant use of MAOIs and CNS stimulants, including Ritalin can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Concomitant use of Ritalin with MAOIs or within 14 days after discontinuing MAOI treatment is contraindicated. Antihypertensive Drugs Clinical Impact Ritalin may decrease the effectiveness of drugs used to treat hypertension.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
84 presentations of Methylphenidate, sorted by availability.
12 brand names across 1 markets.
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Methylphenidate in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 84 presentations of Methylphenidate and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Dr. Reddy's Laboratories.
The catalogue lists 12 brand names for Methylphenidate, including Concerta, Cotempla XR-ODT, Daytrana, JORNAY PM Extended-Release, Metadate CD, Methylin, Methylphenidate Hydrochloride (LA), methylphenidate hydrochloride CD.
Yes. The US FDA first approved Methylphenidate on 5 December 1955, according to Drugs@FDA.
Yes. Methylphenidate has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Methylphenidate must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Methylphenidate is classified under ATC code N06BA04 (Methylphenidate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.